Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective
compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative
symptoms of schizophrenia. Study subjects will be treated with study drug for up to 6 weeks
and will then return for a follow-up visit 2 weeks later. About 275 patients with
schizophrenia will be enrolled in this study.